A new digital solution to help predict respiratory failure in Covid-19 patients who have left critical care has secured funding from government.
The Covid-19 Advanced Respiratory Physiological (CARP) platform is being trialled in respiratory failure patients across Glasgow after securing funding from the Scottish Government’s Chief Scientist Office.
The technology is being developed in partnership between by digital transformation consultancy Storm ID, NHS Greater Glasgow and Clyde and Altair Medical and will help clinicians monitor patients continuously once they’ve left direct care.
A key challenge faced by hospitals in the coronavirus pandemic is the need to monitor an unprecedented number of patients. This is made more challenging by the fact that patients with Covid-19 are at risk of sudden deterioration. Respiratory rate and breathing events are a key predictor of deterioration but, until now, hospitals have been unable to monitor patient respiratory health remotely or at scale.
“CARP will provide us with critical, real-time capability to identify and triage Covid-19 patients at risk of deterioration. This will greatly assist clinicians as patient numbers increase,” said Dr Chris Carlin, Consultant Physician at NHS Greater Glasgow and Clyde.
Dr Bruce Henderson, CEO of Altair Medical, said: “The CARP trial has allowed unique insights into the effects of Covid-19 and the data analysis methods developed will enhance the use of Altair Medical’s technology in a range of respiratory conditions. This would not have been possible without the Lenus Health Platform – it provides a pivotal link in safely and securely maximising the real-world utility of biosensor data.”
